Tempus ECG-AF vs VitalRhythm

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Tempus ECG-AF

by Tempus AI, Inc.

VitalRhythm

by VitalConnect, Inc.

AI Verdict

Tempus ECG-AF is designed for identifying patients at risk of developing new-onset atrial fibrillation within 12 months using a standard 12-lead ECG. In contrast, VitalRhythm provides continuous, AI-powered detection and analysis of various cardiac arrhythmias through a wearable biosensor for remote patient monitoring. While both leverage AI in cardiology, Tempus focuses on predictive risk assessment from a point-in-time ECG, whereas VitalRhythm specializes in ongoing, real-time arrhythmia detection.

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older at increased risk of developing new-onset atrial fibrillation within the next 12 months, utilizing a single 12-lead ECG recording. This tool is ideal for risk stratification and guiding earlier follow-up in a clinical setting for eligible patients without pre-existing AF or cardiac devices.

View Tempus ECG-AF →

Choose VitalRhythm if…

Choose VitalRhythm if you require continuous, long-term monitoring for a broad spectrum of cardiac arrhythmias in patients, especially in a remote patient monitoring context. This cloud-based AI software, integrated with the VitalPatch biosensor, is best suited for detecting and analyzing ongoing or intermittent arrhythmias to support non-urgent clinical decision-making and remote patient management.

View VitalRhythm →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Tempus ECG-AF	VitalRhythm
Pricing	Contact vendor	Unknown
Deployment	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.	Cloud-based
BAA Available	Yes AI-estimated	Unknown
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Tempus ECG-AF	VitalRhythm
Product Name	Tempus ECG-AF	VitalRhythm
Company	Tempus AI, Inc.	VitalConnect
Primary Detection Focus	Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months	Continuous cardiac arrhythmia detection and analysis (e.g., atrial fibrillation, AV block, supraventricular tachycardia, ventricular tachycardia, pauses)
Patient Criteria/Target Population	Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery	Not specified
Monitoring Type	Analyzes 12-lead ECG recordings (single-point analysis)	Continuous ECG signal analysis
Integration/Compatibility	Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems	Integrates with VitalPatch biosensor and Vista Solution platform

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-AF and VitalRhythm.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical application of each tool?

Tempus ECG-AF is an AI-based algorithm that analyzes 12-lead ECGs to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. VitalRhythm is an AI-powered cloud-based software that provides continuous cardiac arrhythmia detection and analysis, integrating with a biosensor for remote patient monitoring.

How do these tools acquire and analyze patient data?

Tempus ECG-AF analyzes data from FDA authorized resting 12-lead ECG recordings from compatible systems like GE Medical Systems and Philips Medical Systems. VitalRhythm integrates with the VitalPatch biosensor to provide continuous ECG signal analysis, with detected arrhythmias displayed for review via the VistaCenter web application.

What specific cardiac conditions can each tool help identify or monitor?

Tempus ECG-AF detects signs associated with new onset Atrial Fibrillation (AF) within 12 months for patients 65 years or older. VitalRhythm detects various cardiac arrhythmias, including atrial fibrillation, AV block, supraventricular tachycardia, ventricular tachycardia, and pauses.

Are there specific patient populations for which each tool is intended?

Tempus ECG-AF is intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. VitalRhythm provides analysis of cardiac arrhythmias in patients who are 18 years of age or older, for outpatient cardiac telemetry and patient monitoring in non-critical healthcare settings.

Is there specific reimbursement information available for either tool?

CMS reimbursement is available for Tempus ECG-AF, utilizing CPT codes 0764T and 0765T, with a Medicare rate of $128.90 effective January 1, 2025. The provided information for VitalRhythm does not specify reimbursement details.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Tempus ECG-AF or VitalRhythm

Backers

Who funded each tool's parent company.